Skip to main content
[Preprint]. 2023 May 23:2023.05.22.540829. [Version 1] doi: 10.1101/2023.05.22.540829

Figure 1. Design and characterization of trivalent RBD scNP vaccines.

Figure 1.

(A) Ferritin nanoparticles were conjugated with sortase A tagged Group 2b SARS-CoV-2 RBD, Group 2b RsSHC014 RBD, and Group 2c MERS-CoV RBD. (B) Visualization of trivalent scNP was performed via negative stain electron microscopy. (C) Validation of trivalent scNP vaccine by Biolayer Interferometry. Trivalent RBD scNP antigenicity was done by assessing binding of the trivalent vaccine and various Group 2b and Group 2c spikes to human ACE2, MERS-CoV RBD mAbs, SARS-CoV-2 RBD mAbs, Group 2b cross-reactive RBD mAbs, and an S2 mAb. HIV-1 envelope was included as a negative control antigen.